Cryolife Inc (NYSE:CRY)’s share price hit a new 52-week high on Friday . The company traded as high as $34.15 and last traded at $33.35, with a volume of 8166 shares. The stock had previously closed at $33.15.

CRY has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Cryolife from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research note on Friday, May 11th. Canaccord Genuity lifted their target price on shares of Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Northland Securities reissued a “buy” rating and set a $32.00 target price on shares of Cryolife in a research note on Tuesday, August 7th. Finally, ValuEngine raised shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 23rd. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Cryolife presently has a consensus rating of “Buy” and an average target price of $31.00.

The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 106.93 and a beta of 0.73. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.72 and a current ratio of 4.97.

Cryolife (NYSE:CRY) last announced its earnings results on Monday, August 6th. The medical equipment provider reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. Cryolife had a negative net margin of 2.34% and a positive return on equity of 4.28%. The business had revenue of $68.50 million during the quarter, compared to the consensus estimate of $64.08 million. During the same quarter last year, the firm earned $0.12 earnings per share. Cryolife’s quarterly revenue was up 43.2% on a year-over-year basis. equities analysts anticipate that Cryolife Inc will post 0.31 earnings per share for the current fiscal year.

In other Cryolife news, Director C Elkins Ronald sold 10,000 shares of Cryolife stock in a transaction on Monday, May 14th. The shares were sold at an average price of $24.75, for a total value of $247,500.00. Following the completion of the sale, the director now directly owns 78,997 shares of the company’s stock, valued at $1,955,175.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP John E. Davis sold 4,373 shares of Cryolife stock in a transaction on Friday, June 1st. The shares were sold at an average price of $28.00, for a total transaction of $122,444.00. The disclosure for this sale can be found here. Insiders have sold 39,028 shares of company stock valued at $1,096,606 in the last three months. 3.97% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Cryolife by 14.5% in the second quarter. BlackRock Inc. now owns 5,103,601 shares of the medical equipment provider’s stock valued at $142,135,000 after purchasing an additional 645,825 shares in the last quarter. Northern Trust Corp increased its stake in Cryolife by 0.6% in the first quarter. Northern Trust Corp now owns 1,170,905 shares of the medical equipment provider’s stock valued at $23,477,000 after purchasing an additional 6,481 shares in the last quarter. Thomson Horstmann & Bryant Inc. increased its stake in Cryolife by 1.8% in the first quarter. Thomson Horstmann & Bryant Inc. now owns 345,581 shares of the medical equipment provider’s stock valued at $6,928,000 after purchasing an additional 6,171 shares in the last quarter. Geode Capital Management LLC increased its stake in Cryolife by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 269,343 shares of the medical equipment provider’s stock valued at $5,157,000 after purchasing an additional 10,483 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Cryolife by 1.9% in the first quarter. Principal Financial Group Inc. now owns 263,759 shares of the medical equipment provider’s stock valued at $5,288,000 after purchasing an additional 5,037 shares in the last quarter. 67.46% of the stock is owned by hedge funds and other institutional investors.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Recommended Story: Growth Stocks

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.